We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Island Pharmaceuticals is a biotechnology business based in Australia. Island Pharmaceuticals shares (ILA) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Island Pharmaceuticals has a market cap (total outstanding shares value) of $11.8 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Island Pharmaceuticals
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Island Pharmaceuticals. Find the share by name or ticker symbol: ILA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Island Pharmaceuticals reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Island Pharmaceuticals. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Our top pick for
US stocks

Our top pick for
Overall broker

Our top pick for
Low-cost broker

Island Pharmaceuticals stock price (ASX:ILA)
Use our graph to track the performance of ILA stocks over time.Island Pharmaceuticals shares at a glance
52-week range | $0.115 - $0.385 |
---|---|
50-day moving average | $0.1626 |
200-day moving average | $0.2409 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.037 |
Compare share trading platforms
Is it a good time to buy Island Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Island Pharmaceuticals price performance over time
Historical closes compared with the last close of A$0.145
1 week (2022-06-23) | 26.09% |
---|---|
1 month (2022-06-03) | -21.62% |
3 months (2022-04-01) | -32.56% |
6 months (2021-12-31) | -43.14% |
1 year (2021-07-02) | -48.21% |
---|
Island Pharmaceuticals financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -40.29% |
Return on equity TTM | -66.48% |
Profit margin | 0% |
Book value | 0.072 |
Market capitalisation | $11.8 million |
TTM: trailing 12 months
Island Pharmaceuticals share dividends
We're not expecting Island Pharmaceuticals to pay a dividend over the next 12 months.
Island Pharmaceuticals overview
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development; cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Stocks similar to Island Pharmaceuticals
Island Pharmaceuticals in the news
Frequently asked questions
More guides on Finder
-
How to invest in the Australia Sunny Glass Group IPO
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
-
How to buy Kincora Copper (KCC) shares
Steps to owning and managing Kincora Copper shares.
-
How to invest in the Dragon Mountain Gold IPO
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
-
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
-
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
-
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
-
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
-
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
-
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
-
How to buy 5E Advanced Materials (5EA) shares
Steps to owning and managing 5E Advanced Materials shares.
Ask an Expert